IP Library › Granted Patent US 12,364,746
Granted Patent B2
US 12,364,746 · App. 17/252,638 · Granted Jul 22, 2025

Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Inventors: Adolfo Garcia-Sastre (New York, NY); Peter Palese (New York, NY); Florian Krammer (New York, NY); Felix Bröcker (Berlin, DE); Weina Sun (New York, NY)
Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A61K39/145A61P31/16A61P37/04C07K14/005C12N7/00G01N33/5091C12N2760/16121C12N2760/16122C12N2760/16123C12N2760/16134C12N2760/16171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,746
App. No.
17/252,638
Granted
Jul 22, 2025
Kind
B2
Abstract

In one aspect, provided herein is a mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the influenza A virus strain HA and an HA globular head domain of the influenza A virus strain HA, wherein the HA globular head domain of the influenza A virus strain HA has been engineered to comprise one or more amino acid substitutions in one, two, three, four or all of the antigenic sites. In another aspect, provided herein are immunogenic compositions comprising such a mosaic influenza virus HA polypeptide or an influenza A virus comprising such a mosaic influenza virus HA polypeptide. In yet another aspect, provided herein are methods for immunizing a subject against an influenza A virus in a subject comprising administering such an immunogenic composition to the subject.

Claims (79)

1. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an HA ectodomain of a first group 2 influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the first group 2 influenza A virus strain HA and an HA globular head domain of the first group 2 influenza A virus strain HA, wherein the HA globular head domain of the first group 2 influenza A virus strain HA comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) antigenic site A of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site A of an HA globular head domain of a second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(b) antigenic site B of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site B of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(c) antigenic site C of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site C of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(d) antigenic site D of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site D of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain; and

(e) antigenic site E of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site E of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

wherein antigenic sites A to E of the first group 2 influenza A virus strain HA and antigenic sites A to E of the second group 2 influenza A virus strain HA correspond to antigenic sites A to E of influenza virus A/Hong Kong/4801/2014 HA (SEQ ID NO: 171); and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the globular head domain of the first group 2 influenza A virus strain HA.

2. The mosaic influenza virus HA polypeptide of claim 1 , wherein the first group 2 influenza A virus strain is a strain of an H3 subtype.

3. The mosaic influenza virus HA polypeptide of claim 2 , wherein the strain of the H3 subtype is influenza virus A/Hong Kong/4801/2014 (H3).

4. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an HA ectodomain of a first group 2 influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the first group 2 influenza A virus strain HA and an HA globular head domain of the first group 2 influenza A virus strain HA, wherein the HA globular head domain of the first group 2 influenza A virus strain HA comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) antigenic site A of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site A of an HA globular head domain of a second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(b) antigenic site B of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site B of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(c) antigenic site C of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site C of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

(d) antigenic site D of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site D of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain; and

(e) antigenic site E of the globular head domain of the first group 2 influenza A virus strain HA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site E of an HA globular head domain of the second group 2 influenza A virus of a different subtype or a different strain than the first group 2 influenza A virus strain;

wherein antigenic sites A to E of the first group 2 influenza A virus strain HA and antigenic sites A to E of the second group 2 influenza A virus strain HA correspond to antigenic sites A to E of influenza virus A/Hong Kong/4801/2014 HA (SEQ ID NO: 171); and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the globular head domain of the first group 2 influenza A virus strain HA; and wherein the second group 2 influenza A virus strain is a strain of an H10 subtype or H14 subtype.

5. The mosaic influenza virus HA polypeptide of claim 1 , which further comprises the transmembrane and cytoplasmic domains of the first group 2 influenza A virus HA.

6. The mosaic influenza virus HA polypeptide of claim 1 , which further comprises a trimerization domain.

7. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza virus A/Hong Kong/4801/2014 (H3) HA, wherein the HA ectodomain comprises an influenza virus A/Hong Kong/4801/2014 (H3) HA stem domain and an influenza virus A/Hong Kong/4801/2014 HA globular head domain, wherein the influenza virus A/Hong Kong/4801/2014 HA globular head comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are amino acid substitutions to amino acid residues found in the antigenic site A of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 HA (H10) or influenza virus A/mallard/Gurjev/263/1982 HA (H14);

(b) antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site B of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 HA (H10) or influenza virus A/mallard/Gurjev/263/1982 HA (H14);

(c) antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site C of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 HA (H10) or influenza virus A/mallard/Gurjev/263/1982 HA (H14);

(d) antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site D of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 HA (H10) or influenza virus A/mallard/Gurjev/263/1982 HA (H14); and

(e) antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site E of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 HA (H10) or influenza virus A/mallard/Gurjev/263/1982 HA (H14); and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain.

8. The mosaic influenza virus HA polypeptide of claim 7 , which further comprises the transmembrane and cytoplasmic domains of the influenza virus A/Hong Kong/4801/2014 HA.

9. The mosaic influenza virus HA polypeptide of claim 7 , which further comprises a trimerization domain.

10. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza virus A/Hong Kong/4801/2014 (H3) HA, wherein the HA ectodomain comprises an influenza virus A/Hong Kong/4801/2014 (H3) HA stem domain and an influenza virus A/Hong Kong/4801/2014 HA globular head domain, wherein the influenza virus A/Hong Kong/4801/2014 HA globular head comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) the amino acid sequence IRRSSSS (SEQ ID NO: 127) in the antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA globular head domain has been substituted with the amino acid sequence MRNGGNS (SEQ ID NO: 128);

(b) the amino acid sequences THLNYK (SEQ ID NO: 15) and TDKDQIFPYA (SEQ ID NO: 130) in the antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences THLNQK (SEQ ID NO: 17) and TDQDQIFPYA (SEQ ID NO: 131), respectively;

(c) the amino acid sequences QNSSIGEICDS (SEQ ID NO: 19) and G-KCKSE (SEQ ID NO: 132) in the antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences ESTGTNRLCMK (SEQ ID NO: 133) and DNNCESK (SEQ ID NO: 134), respectively;

(d) the amino acid sequence KRSQQA (SEQ ID NO: 135) in the antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA globular head domain has been substituted with the amino acid sequence STYQQT (SEQ ID NO: 136); and

(e) the amino acid sequences ENCT (SEQ ID NO: 124), GFQNKKWDLFVERSKAY (SEQ ID NO: 27) and IRSGK (SEQ ID NO: 137) in the antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences GNCH (SEQ ID NO: 125), GFQNKMWDLFVERSKAY (SEQ ID NO: 29) and LRIGR (SEQ ID NO: 138), respectively, and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain.

11. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza virus A/Hong Kong/4801/2014 (H3) HA, wherein the HA ectodomain comprises an influenza virus A/Hong Kong/4801/2014 (H3) HA stem domain and an influenza virus A/Hong Kong/4801/2014 HA globular head domain, wherein the influenza virus A/Hong Kong/4801/2014 HA globular head comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) the amino acid sequence NNESFNWTGVTQNGTSSACIRRSSSS (SEQ ID NO: 13) in the antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA globular head domain has been substituted with the amino acid sequence NNESFNWTGVTQNGTSSACMRNGGNS (SEQ ID NO: 14);

(b) the amino acid sequences THLNYK (SEQ ID NO: 15) and GTDKDQIFLYAQ (SEQ ID NO: 16) in the antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences THLNQK (SEQ ID NO: 17) and GTNQDQIFLYAQ (SEQ ID NO: 18), respectively;

(c) the amino acid sequences QNSSIGEICDS (SEQ ID NO: 19) and PIGKCKSE (SEQ ID NO: 20) in the antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences ESTGTNRLCMK (SEQ ID NO: 133) and PIDNNCESK (SEQ ID NO: 22), respectively;

(d) the amino acid sequence RITVSTKRSQQAVIPNIGS (SEQ ID NO: 23) in the antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA globular head domain has been substituted with the amino acid sequence RITVSTSTYQQAVIPNIGS (SEQ ID NO: 25); and

(e) the amino acid sequences ENCT (SEQ ID NO: 124), GFQNKKWDLFVERSKAY (SEQ ID NO: 27) and IRSGKS (SEQ ID NO:28) in the antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain have been substituted with the amino acid sequences GNCH (SEQ ID NO: 125), GFQNKMWDLFVERSKAY (SEQ ID NO: 29) and LRIGRS (SEQ ID NO: 24), respectively, and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain.

12. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza virus A/Hong Kong/4801/2014 (H3) HA, wherein the HA ectodomain comprises an influenza virus A/Hong Kong/4801/2014 (H3) HA stem domain and an influenza virus A/Hong Kong/4801/2014 HA globular head domain, wherein the influenza virus A/Hong Kong/4801/2014 HA globular head comprises amino acid substitutions in antigenic sites A to E, and wherein:

(a) the amino acid sequence IRRSSSS (SEQ ID NO: 127) in the antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA has been substituted with the amino acid sequence LRGGRNS (SEQ ID NO: 148);

(b) the amino acid sequences THLNYK (SEQ ID NO: 15) and TDKDQIFPYA (SEQ ID NO: 130) in the antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA have been substituted with the amino acid sequences THLNGK (SEQ ID NO: 140) and TDNDQIFPYA (SEQ ID NO: 149), respectively;

(c) the amino acid sequences QNSSIGEICDS (SEQ ID NO: 19) and G-KCKSE (SEQ ID NO: 132) in the antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA have been substituted with the amino acid sequences ETNHTDELCPS (SEQ ID NO: 150) and G-SCTSP (SEQ ID NO: 151), respectively;

(d) the amino acid sequence KRSQQA (SEQ ID NO: 135) in the antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA has been substituted with the amino acid sequence RSDQQT (SEQ ID NO: 152); and

(e) the amino acid sequences ENCT (SEQ ID NO: 124), K83 and IRSGK (SEQ ID NO: 137) in the antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA have been substituted with the amino acid sequences QNCD (SEQ ID NO: 145), 83T, and IRKGK (SEQ ID NO: 153), respectively; and

wherein the mosaic HA polypeptide comprises 0, 1, 2, 3, 4, or 5 amino acid substitutions outside of antigenic sites A to E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain.

13. The mosaic influenza virus HA polypeptide of claim 10 , wherein the mosaic influenza virus HA polypeptide further comprises the transmembrane and cytoplasmic domains of the influenza virus A/Hong Kong/4801/2014 HA.

14. The mosaic influenza virus HA polypeptide of claim 10 , wherein the mosaic influenza virus HA polypeptide further comprises a trimerization domain.

15. A mosaic influenza virus hemagglutinin (HA) polypeptide comprising:

(a) the amino acid sequence set forth in SEQ ID NO: 173; SEQ ID NO: 31; or SEQ ID NO: 175; or

(b) the amino acid sequence set forth in SEQ ID NO: 173 or SEQ ID NO: 175 without the signal peptide.

16. A nucleic acid sequence comprising the nucleotide sequence encoding the mosaic influenza virus HA polypeptide of claim 1 .

17. A nucleic acid sequence comprising the nucleotide sequence encoding the mosaic influenza virus HA polypeptide of claim 7 .

18. A nucleic acid sequence comprising a nucleotide sequence encoding a mosaic influenza virus hemagglutinin (HA) polypeptide of claim 15 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 172 or SEQ ID NO: 174.

19. The nucleic acid sequence of claim 16 , wherein the nucleic acid sequence is RNA.

20. An expression vector comprising the nucleic acid sequence of claim 16 .

21. A viral vector or virus-like particle comprising the mosaic influenza virus HA polypeptide of claim 1 .

22. An influenza A virus comprising the mosaic influenza virus HA polypeptide of claim 1 .

23. An immunogenic composition comprising the mosaic influenza virus HA polypeptide of claim 1 .

24. An immunogenic composition comprising the nucleic acid sequence of claim 16 .

25. An immunogenic composition comprising the influenza A virus of claim 22 .

26. A cell line expressing the mosaic influenza virus HA polypeptide of claim 1 .

27. The immunogenic composition of claim 25 , which further comprises an adjuvant.

28. The mosaic influenza virus HA polypeptide of claim 7 , wherein:

(a) antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are amino acid substitutions to amino acid residues found in the antigenic site A of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 (H10) HA;

(b) antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site B of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 (H10) HA;

(c) antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site C of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 (H10) HA;

(d) antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site D of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 (H10) HA; and

(e) antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site E of an HA globular head domain of influenza virus A/Jiangxi-Donghu/346-1/2013 (H10) HA.

29. The mosaic influenza virus HA polypeptide of claim 7 , wherein:

(a) antigenic site A of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are amino acid substitutions to amino acid residues found in the antigenic site A of an HA globular head domain of influenza virus A/mallard/Gurjev/263/1982 (H14) HA;

(b) antigenic site B of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site B of an HA globular head domain of influenza virus A/mallard/Gurjev/263/1982 (H14) HA;

(c) antigenic site C of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site C of an HA globular head domain of influenza virus A/mallard/Gurjev/263/1982 (H14) HA;

(d) antigenic site D of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site D of an HA globular head domain of influenza virus A/mallard/Gurjev/263/1982 (H14) HA; and

(e) antigenic site E of the influenza virus A/Hong Kong/4801/2014 HA globular head domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the amino acid substitutions are substitutions to amino acid residues found in the antigenic site E of an HA globular head domain of influenza virus influenza virus A/mallard/Gurjev/263/1982 (H14) HA.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 14, 2023
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065566/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: GARCIA-SASTRE, ADOLFO; PALESE, PETER; KRAMMER, FLORIAN; BRÖCKER, FELIX; SUN, WEINA
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 054734/0590 →
Continuity (2)
Provisional Application 62688329 · Jun 21, 2018
Related Publication 20210260179A1 · Aug 26, 2021
References Cited (400)
US 4444887A · Hoffmann · 1984 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4603112A · Paoletti et al. · 1986 [cited by applicant]
US 4693981A · Wiesehahn et al. · 1987 [cited by applicant]
US 4716111A · Osband et al. · 1987 [cited by applicant]
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 4769330A · Paoletti et al. · 1988 [cited by applicant]
US 5057540A · Kensil et al. · 1991 [cited by applicant]
US 5106619A · Wiesehahn et al. · 1992 [cited by applicant]
US 5110587A · Paoletti et al. · 1992 [cited by applicant]
US 5166057A · Palese et al. · 1992 [cited by applicant]
US 5174993A · Paoletti · 1992 [cited by applicant]
US 5182192A · Steplewski et al. · 1993 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5484719A · Lam et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571709A · Devauchelle et al. · 1996 [cited by applicant]
US 5573916A · Cheronis et al. · 1996 [cited by applicant]
US 5589174A · Okuno et al. · 1996 [cited by applicant]
US 5612487A · Lam et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5631350A · Okuno et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643576A · Johnston et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5820871A · Palese et al. · 1998 [cited by applicant]
US 5854037A · Palese et al. · 1998 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5891705A · Budowsky et al. · 1999 [cited by applicant]
US 5914935A · Saito · 1999 [cited by applicant]
US 5916771A · Hori et al. · 1999 [cited by applicant]
US 5929304A · Radin et al. · 1999 [cited by applicant]
US 6001634A · Palese et al. · 1999 [cited by applicant]
US 6022726A · Palese et al. · 2000 [cited by applicant]
US 6034298A · Lam et al. · 2000 [cited by applicant]
US 6136320A · Arntzen et al. · 2000 [cited by applicant]
US 6146642A · Garcia-Sastre et al. · 2000 [cited by applicant]
US 6165476A · Strom et al. · 2000 [cited by applicant]
US 6265189B1 · Paoletti et al. · 2001 [cited by applicant]
US 6337070B1 · Okuno et al. · 2002 [cited by applicant]
US 6468544B1 · Egorov et al. · 2002 [cited by applicant]
US 6544785B1 · Palese et al. · 2003 [cited by applicant]
US 6551820B1 · Mason et al. · 2003 [cited by applicant]
US 6573079B1 · Palese et al. · 2003 [cited by applicant]
US 6635246B1 · Barrett et al. · 2003 [cited by applicant]
US 6649372B1 · Palese et al. · 2003 [cited by applicant]
US 6669943B1 · Palese et al. · 2003 [cited by applicant]
US 6720409B2 · Okuno et al. · 2004 [cited by applicant]
US 6770799B2 · Mor et al. · 2004 [cited by applicant]
US 6852522B1 · Palese et al. · 2005 [cited by applicant]
US 6867293B2 · Andrews et al. · 2005 [cited by applicant]
US 6887699B1 · Palese et al. · 2005 [cited by applicant]
US 6942861B2 · McKee et al. · 2005 [cited by applicant]
US 6951754B2 · Hoffmann · 2005 [cited by applicant]
US 7312064B2 · Hoffmann · 2007 [cited by applicant]
US 7384774B2 · Palese et al. · 2008 [cited by applicant]
US 7442379B2 · Garcia-Sastre et al. · 2008 [cited by applicant]
US 7494808B2 · Palese et al. · 2009 [cited by applicant]
US 7504560B2 · Arntzen et al. · 2009 [cited by applicant]
US 7566458B2 · Yang et al. · 2009 [cited by applicant]
US 7968101B2 · Kawaoka et al. · 2011 [cited by applicant]
US 8367077B2 · Zurbriggen et al. · 2013 [cited by applicant]
US 8603467B2 · Chen et al. · 2013 [cited by applicant]
US 8673314B2 · Sastre et al. · 2014 [cited by applicant]
US 8828406B2 · Garcia-Sastre et al. · 2014 [cited by applicant]
US 9051359B2 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 9175069B2 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 9371366B2 · Garcia-Sastre et al. · 2016 [cited by applicant]
US 9452211B2 · Meijberg et al. · 2016 [cited by applicant]
US 9701723B2 · Garcia-Sastre et al. · 2017 [cited by applicant]
US 9707288B2 · Schrader · 2017 [cited by applicant]
US 9708373B2 · Garcia-Sastre et al. · 2017 [cited by applicant]
US 9849172B2 · Garcia-Sastre et al. · 2017 [cited by applicant]
US 9908930B2 · Palese et al. · 2018 [cited by applicant]
US 9968670B2 · Garcia-Sastre et al. · 2018 [cited by applicant]
US 10131695B2 · Garcia-Sastre et al. · 2018 [cited by applicant]
US 10137189B2 · Garcia-Sastre et al. · 2018 [cited by applicant]
US 10179806B2 · Garcia-Sastre et al. · 2019 [cited by applicant]
US 10544207B2 · Palese et al. · 2020 [cited by applicant]
US 10583188B2 · Garcia-Sastre et al. · 2020 [cited by applicant]
US 10736956B2 · Palese et al. · 2020 [cited by applicant]
US 11254733B2 · Palese et al. · 2022 [cited by applicant]
US 11266734B2 · Palese et al. · 2022 [cited by applicant]
US 11865173B2 · Palese et al. · 2024 [cited by applicant]
US 20020054882A1 · Okuno et al. · 2002 [cited by applicant]
US 20020164770A1 · Hoffman · 2002 [cited by applicant]
US 20030134338A1 · Makarocskiy · 2003 [cited by applicant]
US 20040002061A1 · Kawaoka · 2004 [cited by applicant]
US 20040073011A1 · Hagay et al. · 2004 [cited by applicant]
US 20050009008A1 · Robinson et al. · 2005 [cited by applicant]
US 20050042229A1 · Yang et al. · 2005 [cited by applicant]
US 20050048074A1 · Cardineau et al. · 2005 [cited by applicant]
US 20050064391A1 · Segal et al. · 2005 [cited by applicant]
US 20050106178A1 · O'hagan et al. · 2005 [cited by applicant]
US 20050201946A1 · Friede et al. · 2005 [cited by applicant]
US 20060008473A1 · Yana et al. · 2006 [cited by applicant]
US 20060019350A1 · Palese et al. · 2006 [cited by applicant]
US 20060204487A1 · Shaaltiel et al. · 2006 [cited by applicant]
US 20060217338A1 · Lu et al. · 2006 [cited by applicant]
US 20060280754A1 · Garry et al. · 2006 [cited by applicant]
US 20070020238A1 · Baltimore et al. · 2007 [cited by applicant]
US 20070036809A1 · Michl et al. · 2007 [cited by applicant]
US 20070207171A1 · Dubensky et al. · 2007 [cited by applicant]
US 20070275014A1 · Yusibov et al. · 2007 [cited by applicant]
US 20080019998A1 · Wang et al. · 2008 [cited by applicant]
US 20080032921A1 · Alexander et al. · 2008 [cited by applicant]
US 20080038232A1 · Shaaltiel et al. · 2008 [cited by applicant]
US 20080152657A1 · Horowitz et al. · 2008 [cited by applicant]
US 20080176247A1 · Chou et al. · 2008 [cited by applicant]
US 20080193455A1 · Stassen et al. · 2008 [cited by applicant]
US 20080207550A1 · Fearon et al. · 2008 [cited by applicant]
US 20080248066A1 · Dubensky et al. · 2008 [cited by applicant]
US 20080254060A1 · Palese et al. · 2008 [cited by applicant]
US 20090053762A1 · Shaaltiel · 2009 [cited by applicant]
US 20090068221A1 · Morrison · 2009 [cited by applicant]
US 20090081255A1 · Bublot et al. · 2009 [cited by applicant]
US 20090082548A1 · Shaaltiel et al. · 2009 [cited by applicant]
US 20090169547A1 · Sahin et al. · 2009 [cited by applicant]
US 20090208477A1 · Shaaltiel et al. · 2009 [cited by applicant]
US 20090246830A1 · Kawaoka et al. · 2009 [cited by applicant]
US 20090291472A1 · Lu et al. · 2009 [cited by applicant]
US 20090304730A1 · Amon et al. · 2009 [cited by applicant]
US 20090304739A1 · Rappouli et al. · 2009 [cited by applicant]
US 20090311265A1 · Van Den Brink et al. · 2009 [cited by applicant]
US 20090311669A1 · Kawaoka · 2009 [cited by applicant]
US 20100184192A1 · Smith et al. · 2010 [cited by applicant]
US 20100247571A1 · Wong et al. · 2010 [cited by applicant]
US 20100297165A1 · Berzofsky et al. · 2010 [cited by applicant]
US 20100297174A1 · Garcia-Sastre et al. · 2010 [cited by applicant]
US 20110027270A1 · Garcia-Sastre et al. · 2011 [cited by applicant]
US 20110111494A1 · Hill et al. · 2011 [cited by applicant]
US 20110182938A1 · Weiner et al. · 2011 [cited by applicant]
US 20110300604A1 · Kawaoka et al. · 2011 [cited by applicant]
US 20120039898A1 · Throsby et al. · 2012 [cited by applicant]
US 20120058538A1 · Palese et al. · 2012 [cited by applicant]
US 20120122185A1 · Palese et al. · 2012 [cited by applicant]
US 20120189658A1 · Couture et al. · 2012 [cited by applicant]
US 20120244183A1 · Garcia-Sastre et al. · 2012 [cited by applicant]
US 20120294796A1 · Johnson et al. · 2012 [cited by applicant]
US 20130022623A1 · Karsunky et al. · 2013 [cited by applicant]
US 20130129747A1 · Schrader · 2013 [cited by applicant]
US 20130129761A1 · Garcia-Sastre et al. · 2013 [cited by applicant]
US 20130209499A1 · Garcia-Sastre et al. · 2013 [cited by applicant]
US 20130224187A1 · Rother et al. · 2013 [cited by applicant]
US 20130315929A1 · Bock · 2013 [cited by applicant]
US 20140004149A1 · Tobin et al. · 2014 [cited by applicant]
US 20140170163A1 · Sastre et al. · 2014 [cited by applicant]
US 20140193484A1 · Bertholet Girardin et al. · 2014 [cited by applicant]
US 20140328875A1 · Sastre et al. · 2014 [cited by applicant]
US 20150132253A1 · Sahin et al. · 2015 [cited by applicant]
US 20150132330A1 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 20150239960A1 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 20150252103A1 · Sahin et al. · 2015 [cited by applicant]
US 20150266951A1 · Song · 2015 [cited by applicant]
US 20150297712A1 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 20150299270A1 · Galarza et al. · 2015 [cited by applicant]
US 20150335729A1 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 20150352202A1 · Osorio et al. · 2015 [cited by applicant]
US 20160015828A1 · Torgov et al. · 2016 [cited by applicant]
US 20160017025A1 · Samira et al. · 2016 [cited by applicant]
US 20160022806A1 · Weiner et al. · 2016 [cited by applicant]
US 20160024196A1 · Majeti et al. · 2016 [cited by applicant]
US 20160038585A1 · Dormitzer et al. · 2016 [cited by applicant]
US 20160067328A1 · Wu et al. · 2016 [cited by applicant]
US 20160137721A1 · Palese et al. · 2016 [cited by applicant]
US 20160185860A1 · Sahin et al. · 2016 [cited by applicant]
US 20160311918A1 · Wang et al. · 2016 [cited by applicant]
US 20160355553A1 · Meijberg et al. · 2016 [cited by applicant]
US 20160355590A1 · Epstein · 2016 [cited by applicant]
US 20160361408A1 · Garcia-Sastre et al. · 2016 [cited by applicant]
US 20160362455A1 · Meijberg et al. · 2016 [cited by applicant]
US 20160376347A1 · Saelens et al. · 2016 [cited by applicant]
US 20170204177A1 · Wang et al. · 2017 [cited by applicant]
US 20170327565A1 · Schrader · 2017 [cited by applicant]
US 20180002385A1 · Garcia-Sastre et al. · 2018 [cited by applicant]
US 20180008696A1 · Palese et al. · 2018 [cited by applicant]
US 20180022804A1 · Peters et al. · 2018 [cited by applicant]
US 20180265573A1 · Palese et al. · 2018 [cited by applicant]
US 20180312592A1 · Junutula et al. · 2018 [cited by applicant]
US 20180333479A1 · Garcia-Sastre et al. · 2018 [cited by applicant]
US 20190048324A1 · Kawaoka et al. · 2019 [cited by applicant]
US 20190099484A1 · Garcia-Sastre et al. · 2019 [cited by applicant]
US 20190106461A1 · Garcia-Sastre et al. · 2019 [cited by applicant]
US 20190125859A1 · Palese et al. · 2019 [cited by applicant]
US 20190292229A1 · Blackledge et al. · 2019 [cited by applicant]
US 20190314485A1 · Palese et al. · 2019 [cited by applicant]
US 20200223905A1 · Palese et al. · 2020 [cited by applicant]
US 20210246432A1 · Kawaoka et al. · 2021 [cited by applicant]
US 20220153873A1 · Krammer et al. · 2022 [cited by applicant]
US 20220249652A1 · Palese et al. · 2022 [cited by applicant]
US 20220257749A1 · Palese et al. · 2022 [cited by applicant]
US 20220363736A1 · Palese et al. · 2022 [cited by applicant]
CA 2121559A1 · 1994 [cited by applicant]
CA 2718923A1 · 2009 [cited by applicant]
CN 1196788C · 2005 [cited by applicant]
CN 103665155A · 2014 [cited by applicant]
CN 104185476A · 2014 [cited by applicant]
CN 105263516A · 2016 [cited by applicant]
EP 0621339A2 · 1994 [cited by applicant]
EP 0702085A1 · 1996 [cited by applicant]
EP 0780475A1 · 1997 [cited by applicant]
EP 2540312A1 · 2013 [cited by applicant]
JP H789992A · 1995 [cited by applicant]
JP H10502168A · 1998 [cited by applicant]
JP 2004258814A · 2004 [cited by applicant]
JP 2006347922A · 2006 [cited by applicant]
JP 2008249712A · 2008 [cited by applicant]
JP 2009022186A · 2009 [cited by applicant]
JP 2009131237A · 2009 [cited by applicant]
JP 2012521786A · 2010 [cited by applicant]
JP 2011057653A · 2011 [cited by applicant]
JP 2012530499A · 2012 [cited by applicant]
JP 2014530003A · 2014 [cited by applicant]
JP 2016508133A · 2016 [cited by applicant]
WO WO1984000687A1 · 1984 [cited by applicant]
WO WO1991010741A1 · 1991 [cited by applicant]
WO WO1992001047A1 · 1992 [cited by applicant]
WO WO1994009136A1 · 1994 [cited by applicant]
WO WO1994012629A1 · 1994 [cited by applicant]
WO WO1994016109A1 · 1994 [cited by applicant]
WO WO1994017826A1 · 1994 [cited by applicant]
WO WO1995034324A1 · 1995 [cited by applicant]
WO WO1996011279A2 · 1996 [cited by applicant]
WO WO1996033735A1 · 1996 [cited by applicant]
WO WO1996034096A1 · 1996 [cited by applicant]
WO WO1996034625A1 · 1996 [cited by applicant]
WO WO1997006270A1 · 1997 [cited by applicant]
WO WO1997012032A1 · 1997 [cited by applicant]
WO WO1997040161A1 · 1997 [cited by applicant]
WO WO1997040177A1 · 1997 [cited by applicant]
WO WO1998002530A1 · 1998 [cited by applicant]
WO WO1998013501A2 · 1998 [cited by applicant]
WO WO1998016654A1 · 1998 [cited by applicant]
WO WO1998024893A2 · 1998 [cited by applicant]
WO WO1998046645A2 · 1998 [cited by applicant]
WO WO1998050433A2 · 1998 [cited by applicant]
WO WO1998053078A1 · 1998 [cited by applicant]
WO WO1999002657A1 · 1999 [cited by applicant]
WO WO1999015672A1 · 1999 [cited by applicant]
WO WO2001004333A1 · 2001 [cited by applicant]
WO WO2002000885A2 · 2002 [cited by applicant]
WO WO2003068923A2 · 2003 [cited by applicant]
WO WO2003068923A3 · 2003 [cited by applicant]
WO WO2005000901A2 · 2005 [cited by applicant]
WO WO2007045674A1 · 2007 [cited by applicant]
WO WO2007064802A1 · 2007 [cited by applicant]
WO WO2007103322A2 · 2007 [cited by applicant]
WO WO2007109812A2 · 2007 [cited by applicant]
WO WO2007109813A1 · 2007 [cited by applicant]
WO WO2007110776A1 · 2007 [cited by applicant]
WO WO2007134237A2 · 2007 [cited by applicant]
WO WO2007134327A2 · 2007 [cited by applicant]
WO WO2008005777A2 · 2008 [cited by applicant]
WO WO2008028946A2 · 2008 [cited by applicant]
WO WO2008032219A2 · 2008 [cited by applicant]
WO WO2009001217A2 · 2008 [cited by applicant]
WO WO2009009876A1 · 2009 [cited by applicant]
WO WO2009012489A1 · 2009 [cited by applicant]
WO WO2009025770A2 · 2009 [cited by applicant]
WO WO2009036157A1 · 2009 [cited by applicant]
WO WO2009068992A1 · 2009 [cited by applicant]
WO WO2009076778A1 · 2009 [cited by applicant]
WO WO2009079259A2 · 2009 [cited by applicant]
WO WO2009092038A1 · 2009 [cited by applicant]
WO WO2009121004A2 · 2009 [cited by applicant]
WO WO2009150532A1 · 2009 [cited by applicant]
WO WO2009156405A1 · 2009 [cited by applicant]
WO WO2010003235A1 · 2010 [cited by applicant]
WO WO2010036170A1 · 2010 [cited by applicant]
WO WO2010036948A2 · 2010 [cited by applicant]
WO WO2010117786A1 · 2010 [cited by applicant]
WO WO2010130636A1 · 2010 [cited by applicant]
WO WO2010138564A1 · 2010 [cited by applicant]
WO WO2010148511A1 · 2010 [cited by applicant]
WO WO2011014645A1 · 2011 [cited by applicant]
WO WO2011044152A1 · 2011 [cited by applicant]
WO WO2011087092A1 · 2011 [cited by applicant]
WO WO2011103453A2 · 2011 [cited by applicant]
WO WO2011111966A2 · 2011 [cited by applicant]
WO WO2011123495A1 · 2011 [cited by applicant]
WO WO2011126370A1 · 2011 [cited by applicant]
WO WO2012009790A1 · 2012 [cited by applicant]
WO WO2013043729A1 · 2013 [cited by applicant]
WO WO2013079473A1 · 2013 [cited by applicant]
WO WO2014159960A1 · 2014 [cited by applicant]
WO WO2014099931A1 · 2014 [cited by applicant]
WO WO2014152841A1 · 2014 [cited by applicant]
WO WO2015199564A1 · 2015 [cited by applicant]
WO WO2016005480A1 · 2016 [cited by applicant]
WO WO2016005482A1 · 2016 [cited by applicant]
WO WO2016118937A1 · 2016 [cited by applicant]
WO WO2016205347A1 · 2016 [cited by applicant]
WO WO2017021893A1 · 2017 [cited by applicant]
WO WO2017035479A1 · 2017 [cited by applicant]
WO WO2017053413A1 · 2017 [cited by applicant]
WO WO2017136575A1 · 2017 [cited by applicant]
WO WO2017136575A8 · 2017 [cited by applicant]
WO WO2017148889A1 · 2017 [cited by applicant]
WO WO2017210445A1 · 2017 [cited by applicant]
WO WO2017218624A1 · 2017 [cited by applicant]
WO WO2018089407A1 · 2018 [cited by applicant]
WO WO2018148383A1 · 2018 [cited by applicant]
WO WO2018187706A2 · 2018 [cited by applicant]
WO WO2019032463A1 · 2019 [cited by applicant]
WO WO2020219719A1 · 2020 [cited by applicant]
WO WO2020264141A1 · 2020 [cited by applicant]
WO WO2021081120A1 · 2021 [cited by applicant]
WO WO2023167868A2 · 2023 [cited by applicant]
WO WO2023167868A3 · 2023 [cited by applicant]
Suntrongwong et al., Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand, 2017, PLoS ONE, vol. 12, No. 12. [cited by examiner]
Abe et al., 2004, “Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin,” J Virol., 78(18):9605-9611. [cited by applicant]
Abed et al., 2002, “Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada,” J. Med. Virol., 67(4):589-595. [cited by applicant]
Air et al., 1985, “Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase,” Virology, 145(2):237-248. [cited by applicant]
Air et al., 1990, “Antigenic, sequence, and crystal variation in influenza B neuraminidase,” Virology, 177(2):578-587. [cited by applicant]
Air et al., 2012, “Influenza neuraminidase,” Influenza Other Respir Viruses, 6(4):245-256 (Epub 2011). [cited by applicant]
Air, “Influenza virus antigenicity and broadly neutralizing epitopes,” Curr. Opin. Virol. 11:113-121 (2015). [cited by applicant]
Altman et al., 2018, “Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift,” Viral. Immunol., 31(2):142-149. [cited by applicant]
Altschul et al., 1997, “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402. [cited by applicant]
Amanat et al., 2019, “Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model,” Emerg. Microbes. Infect., 8(1):155-168. [cited by applicant]
Angeletti et al., 2017, “Defining B cell immunodominance to viruses,” Nat Immunol., 18(4):456-463. [cited by applicant]
Angeletti et al., 2018, “Is It Possible to Develop a “Universal” Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination,” Cold Spring Harb Perspect Biol., 10(7):a028… [cited by applicant]
Anonymous, “alignment” IBIS—Integrated Biotechnological Information, European Patent Office, retrieved from ibis.internal.epo.org/exam/jobResult?id=285344, on Sep. 26, 2014 (1 page). [cited by applicant]
Anonymous, “Amino Acids Reference Chart—Sigma-Aldrich” retrieved from www.sigmaaldrich.com/life-science/metabolomics/learning-center/amino-acid-reference-chart.html, on Jul. 17, 2015 (3 pages). [cited by applicant]
Anthony et al., 2012, “Emergence of fatal avian influenza in New England harbor seals,” MBio., 3(4):e00166-12. [cited by applicant]
Antoine et al., 1998, “The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses,” Virology, 244(2):365-396. [cited by applicant]
Arzey et al., 2012, “Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia,” Emerg Infect Dis., 18(5):814-816. [cited by applicant]
Babai et al., “A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin- neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influ… [cited by applicant]
Babu et al., “Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine,” Vaccine 32:6798-6804 (2014). [cited by applicant]
Bailey et al., 2018, “A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies,” J. Vis. Exp., (132):e56256 (5 pages). [cited by applicant]
Baker et al., 1976, “Effect of Ca++ on the stability of influenza virus neuraminidase,” Arch Virol., 52(1-2):7-18. [cited by applicant]
Baker et al., 2013, “Protection against lethal influenza with a viral mimic,” J Virol., 87(15):8591-8605. [cited by applicant]
Basler et al., 1999, “Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses,” J Virol., 73(10):8095-8103. [cited by applicant]
Baz et al., 2013, “Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets,” J Virol., 87(12):6901-6910. [cited by applicant]
Beare et al., 1975, “Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses,” Lancet, 2(7938):729-732. [cited by applicant]
Belongia et al., 2016, “Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies,” Lancet Infect. Dis., 16(8):942-951. [cited by applicant]
Belshe, 2007, “Translational research on vaccines: influenza as an example,” Clin Pharmacol Ther., 82(6):745-749. [cited by applicant]
Benjamin et al., 2014, “A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head,” J. Virol., 88(12):6743-6750. [cited by applicant]
Benne et al., 1998, “Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals,” Clin. Diagn. Lab Immunol., 5(1):… [cited by applicant]
Benoit et al., 2015, “Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease,” Open Forum Infect. Dis., 2(2):ofv067 (8 pages). [cited by applicant]
Berry, “Cross-reactive MAb to the binding domain of botulinum neurotoxin A, B, and E developed using a sequential immunization strategy: anti-botulinum neurotoxin,” Hybridoma 26(6):435-436 (2007). [cited by applicant]
Bett et al., 1993, “Packaging capacity and stability of human adenovirus type 5 vectors,” J Virol., 67(10):5911-5921. [cited by applicant]
Beyer et al., 2013, “Cochrane re-arranged: support for policies to vaccinate elderly people against influenza,” Vaccine, 31(50):6030-6033. [cited by applicant]
Bhatt et al., 2011, “The genomic rate of molecular adaptation of the human influenza A virus,” Mol. Biol. Evol., 28(9):2443-2451. [cited by applicant]
Bianchi et al., “Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor,” J. Virol. 79(12):7380-7388 (2005). [cited by applicant]
Bommakanti et al., “Design of an HA2-based [cited by applicant]
Bommakanti et al., “Design of Eschericia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge,” J. Virol. 86(24):13434-13444 (2012). [cited by applicant]
Boni et al., “Guidelines for identifying homologous recombination events in influenza A virus,” PLoS One 5(5):e10434 (2010). [cited by applicant]
Boni et al., “No evidence for intra-segment recombination of 2009 H1N1 influenza virus in swine,” Gene 494(2):242-245 (2012). [cited by applicant]
Bouvier et al., 2008, “Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol,” J Virol., 82(20):10052-10058. [cited by applicant]
Bouvier et al., 2010, “Animal Models for Influenza Virus Pathogenesis and Transmission, ” Viruses, 2(8):1530-1563. [cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247:1306-1310 (1990). [cited by applicant]
Bright et al., 2007, “Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin,” Vaccine, 25(19):3871-3878. [cited by applicant]
Broecker et al., 2018, “Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice,” J Virol., 92(20):e01100-18. [cited by applicant]
Broecker et al., 2019, “A Mosaic Hemagglutinin-Based Influenza Virus Vaccine Candidate Protects Mice From Challenge With Divergent H3N2 Strains,” NPJ Vaccines, 4:31 (9 pages). [cited by applicant]
Broecker et al., 2019, “Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase,” J. Virol., 93(18):e00840-19 (12 pages). [cited by applicant]
Brottet et al., 2014, “Influenza season in Réunion dominated by influenza B virus circulation associated with numerous cases of severe disease, France, 2014,” Eurosurveillance (4 pages). [cited by applicant]
Bruhn et al., 2014, “Crystal structure of the nipah virus phosphoprotein tetramerization domain,” J Virol., 88(1):758-762 (Epub 2013). [cited by applicant]
Budd et al., 2018, “Update: Influenza Activity—United States, Oct. 1, 2017-Feb. 3, 2018,” MMWR Morb Mortal Wkly Rep., 67(6):169-179. [cited by applicant]
Bullough et al., “Structure of influenza haemagglutinin at the pH of membrane fusion,” Nature 371:37-43 (1994). [cited by applicant]
Carter et al., 2016, “Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses,” J Virol., 90(9):4720-4734. [cited by applicant]
Casali et al., “Site-directed mutagenesis of the hinge peptide from the hemagglutinin protein: enhancement of the pH-responsive conformational change,” Protein Eng. Des. Sel. 21(6):395-404 (2008). [cited by applicant]
Castrucci et al., 1993, “Biologic importance of neuraminidase stalk length in influenza A virus,” J. Virol., 67(2):759-764. [cited by applicant]
Caton et al., 1982, “The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype),” Cell, 31(2 Pt 1):417-427. [cited by applicant]
Centers for Disease Control and Prevention Metropolitan Atlanta Congenital Defects Program (CDC MACDP) guidelines. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies; http://www.c… [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2009, “Swine influenza A (H1N1) infection in two children—Southern California, Mar.-Apr. 2009,” MMWR Morb Mortal Wkly Rep., 58(15):400-402. [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2009, “Update on influenza A (H1N1) 2009 monovalent vaccines,” MMWR Morb Mortal Wkly Rep., 58(39):1100-1101. [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2010, “Estimates of deaths associated with seasonal influenza—United States, 1976-2007,” MMWR Morb Mortal Wkly Rep., 59(33):1057-1062. [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2011, “Influenza-Associated Pediatric Deaths—United States, Sep. 2010-Aug. 2011,” MMWR Morb Mortal Wkly Rep., 60(36):1233-1267. [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2012, “Notes from the field: Highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers—Jalisco, Mexico, Jul. 2012,” MMWR Morb Mortal Wkly Rep., 6… [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2012, “Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair—Indiana, Jul. 2012,” MMWR Morb Mortal Wkly Rep., 61(29):561. [cited by applicant]
Centers for Disease Control and Prevention (CDC), 2018, “Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness—United States, Feb. 2018,” MMWR Morb Mortal Wkly Rep., 67(6);180-185. [cited by applicant]
Chen et al., “Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs,” J. Virol. 84(1):44-51 (2010). [cited by applicant]
Chen et al., “Influenza Virus Hemagglutinin and Neuraminidase, but Not the Matrix Protein, Are Required for Assembly and Budding of Plasmid-Derived Virus-Like Particles,” J. Virol. 81(13):7111-7123 (2007). [cited by applicant]
Chen et al., “N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA2 subunit to form an N cap that terminates the triple-stranded coiled coil,” Proc. Natl. Acad. Sci. 96(16):8967-8972 (1999). [cited by applicant]
Chen et al., “Vaccine design of hemagglutinin glycoprotein against influenza,” Trends Biotechnol. 29(9):426-434 (2011). [cited by applicant]
Chen et al., 2000, “Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase,” Vaccine, 18(28):3214-3222. [cited by applicant]
Chen et al., 2007, “Exploration of the emergence of the Victoria lineage of influenza B virus,” Arch Virol., 152(2):415-422 (Epub 2006). [cited by applicant]
Chen et al., 2009, “Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets,” J Virol., 83(1):65-72. [cited by applicant]
Chen et al., 2012, “The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets,” Vaccine, 30(15):2516-2522. [cited by applicant]
Chen et al., 2014, “Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study,” Lancet, 383(9918):714-721. [cited by applicant]
Chen et al., 2016, “Influenza A viruses expressing intra- or inter-group chimeric hemagglutinins,” 90:3789-3793, doi: 10.1128/JVI.03060-15. [cited by applicant]
Chen et al., 2018, “Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies,” Cell, 173(2):417-429. [cited by applicant]
Chromikova et al., 2017, “Generation of a serum free Cho DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody,” PLoS One, 12(9):e0183315 (11 pages). [cited by applicant]
Claas et al., 1998, “Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus,” Lancet, 351(9101):472-477. [cited by applicant]
Clementi et al., “A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes,” PLoS ONE 6(12):e28001 (2011). [cited by applicant]
Clements et al., 1986, “Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus,” J. Clin. Microbiol., 24(1):157-160. [cited by applicant]
Cobey et al., 2017, “Immune history and influenza virus susceptibility,” Curr. Opin. Virol., 22:105-111. [cited by applicant]
Cohen et al., 2013, “Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase,” Virol J., 10:321 (13 pages). [cited by applicant]
Communie et al., 2013, “Structure of the tetramerization domain of measles virus phosphoprotein,” J Virol., 87(12):7166-7169. [cited by applicant]
Copeland et al., “Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin,” J. Virol. 79:6459-6471 (2005). [cited by applicant]
Corti et al., “A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,” Science 333(6044):850-856 (2011). [cited by applicant]
Corti et al., 2010, “Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine,” J Clin Invest., 120(5):1663-1673. [cited by applicant]
Cotter et al., “A Single Amino Acid in the Stalk Region of the H1N1pdm Influenza Virus HA Protein Affects Viral Fusion, Stability and Infectivity,” PLoS Pathogens 10(1):e1003831 (2014). [cited by applicant]
Couch et al., 1974, “Induction of partial immunity to influenza by a neuraminidase-specific vaccine,” J Infect Dis., 129(4):411-420. [cited by applicant]
Couch et al., 2012, “A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine,” PLoS One, 7(12):e49704 (6 pages). [cited by applicant]
Couch et al., 2012, “Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines,” Vaccine, 31(1):190-195. [cited by applicant]
Couch et al., 2013, “Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase,” J Infect Dis., 207(6):974-981. [cited by applicant]
Coudeville et al., 2010, “Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model,” BMC Med. Res. Metho… [cited by applicant]
Cox and Fukuda, “Influenza,” Infect. Dis. Clin. North Am. 12(1):27-38 (1998). [cited by applicant]
Cited By (1)
US 12,545,718